Homoarginine and inhibition of human arginase activity: kinetic characterization and biological relevance

S. Tommasi¹, D.J. Elliot¹, M. Da Boit², S.R. Gray³, B.C. Lewis^{1,4}, A.A. Mangoni^{1*}

¹Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University and Flinders Medical Centre, Adelaide, Australia;

²Faculty of Health and Life Sciences, De Montfort University, Leicester, United Kingdom;

³Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom;

⁴Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Adelaide, Australia;

SUPPLEMENTARY FIGURES

anti-arginase 1




Figure S1. Expression of recombinant arginase 1 and arginase 2 in HEK293T cell lysate as shown by representative western blots performed using anti-arginase 1. Each blot shows: molecular markers (lane 1), untransfected HEK293T cell lysate (lane 2, 100 μ g), arginase 1 lysate (lane 3, 30 μ g), and arginase 2 lysate (lane 4, 30 μ g).

anti-arginase 2




Figure S2. Expression of recombinant arginase 1 and arginase 2 in HEK293T cell lysate as shown by representative western blots performed using anti-arginase 2. Each blot shows: molecular markers (lane 1), untransfected HEK293T cell lysate (lane 2, 100 μ g), arginase 1 lysate (lane 3, 30 μ g), and arginase 2 lysate (lane 4, 30 μ g).

anti-FLAG




Figure S3. Expression of recombinant arginase 1 and arginase 2 in HEK293T cell lysate as shown by representative western blots performed using anti-FLAG. Each blot shows: molecular markers (lane 1), untransfected HEK293T cell lysate (lane 2, 100 μ g), arginase 1 lysate (lane 3, 30 μ g), and arginase 2 lysate (lane 4, 30 μ g).